Clinical Trials

Phase 1 Active not recruiting

Melanoma, Neoplasms

NCT01955460 2026-04-15

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

34 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Melanoma

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1 Recruiting

48 enrolled

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05628883 2026-04-02

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

17 enrolled

Phase 2 Active not recruiting

Uveal Melanoma, Melanoma

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

1,230 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Melanoma, Meningeal Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT06204991 2025-08-24

ADP-TILIL7

Phase 1 Recruiting

10 enrolled

Phase EARLY_PHASE1 Completed

Melanoma

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

11 enrolled

Melanoma, Skin Neoplasms

NCT04904185 2025-07-25

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Phase 1 Terminated

8 enrolled 8 charts

Melanoma

NCT06190249 2025-06-05

LN-144

Phase 1 Withdrawn

Melanoma

NCT02500576 2025-01-15

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

18 enrolled 13 charts

Melanoma

NCT01740557 2024-10-08

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase 1/2 Completed

10 enrolled 10 charts

Melanoma

NCT02959905 2023-02-02

Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

DermatologicGastrointestinal

11 enrolled

Melanoma, Colorectal Neoplasms

NCT01807182 2022-11-10

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

11 enrolled 12 charts

Melanoma

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Phase 1 Unknown

20 enrolled

Melanoma

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

DermatologicGastrointestinalGynecologicHead & Neck

18 enrolled

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT03158935 2020-08-14

ACTIVATE

8 enrolled

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

12 enrolled